Golimumab for the treatment of psoriatic arthritis

  • Technology appraisal guidance
  • TA220
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by the NHS Centre for Reviews and Dissemination and Centre for Health Economics:

  • Yang H, Epstein D, Bojke L, Craig D et al. (August 2010). Golimumab for the treatment of psoriatic arthritis. York: NHS Centre for Reviews and Dissemination and Centre for Health Economics, University of York.

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist, patient or carer groups, and other consultees had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist, patient or carer groups, and other consultees also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Centocor/Schering-Plough

Professional or specialist, and patient or carer groups:

  • Psoriasis and Psoriatic Arthritis Alliance

  • Psoriasis Association

  • British Association of Dermatologists

  • British Health Professionals in Rheumatology

  • British Society for Rheumatology

  • Primary Care Rheumatology Society

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

Other consultees:

  • Department of Health

  • NHS Haringey

  • NHS Havering

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Abbott (adalimumab)

  • Pfizer (methotrexate, sulfasalazine)

  • Sanofi-Aventis (leflunomide)

  • National Institute for Health Research Health Technology Assessment Programme

  • NHS Centre for Reviews & Dissemination and Centre for Health Economics – York

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on golimumab for the treatment of psoriatic arthritis by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Eleanor Korendowych, Consultant Rheumatologist, nominated by British Society for Rheumatology – clinical specialist

  • Alex Anstey, Consultant Dermatologist, nominated by British Association of Dermatologists – clinical specialist

  • Philip Helliwell, nominated by British Society of Rheumatology – clinical specialist

  • Jana James, nominated by Psoriasis and Psoriatic Arthritis Alliance – patient expert

The following individual was nominated as NHS Commissioning expert by the selected NHS trust allocated to this appraisal. She gave her NHS commissioning personal view on golimumab for the treatment of psoriatic arthritis by attending the initial Committee discussion and providing written evidence to the Committee. She was also invited to comment on the ACD.

  • Sue Ashwell, Chief Pharmacist, NHS Cambridgeshire selected by NHS Havering – NHS Commissioning expert

Representatives from the following manufacturer or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy:

  • Merck Sharp & Dohme (formerly Schering-Plough)